Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 438,066 shares of the biopharmaceutical company’s stock after selling 3,230 shares during the period. Intra-Cellular Therapies comprises approximately 1.4% of Emerald Advisers LLC’s holdings, making the stock its 15th biggest position. Emerald Advisers LLC owned 0.41% of Intra-Cellular Therapies worth $36,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Intra-Cellular Therapies by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after acquiring an additional 93,107 shares in the last quarter. Wasatch Advisors LP boosted its holdings in shares of Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after buying an additional 130,351 shares during the period. Bellevue Group AG boosted its holdings in shares of Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after buying an additional 14,342 shares during the period. State Street Corp boosted its holdings in shares of Intra-Cellular Therapies by 3.1% in the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after buying an additional 56,664 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after buying an additional 155,655 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Trading Up 0.0 %

Shares of Intra-Cellular Therapies stock opened at $131.65 on Friday. The firm has a fifty day simple moving average of $128.61 and a 200-day simple moving average of $97.59. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.67. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of -151.32 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analysts Set New Price Targets

ITCI has been the topic of several recent research reports. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.